Cic edizioni internazionali
Functional Neurology

Anti-osteoporotic treatments in neurological
diseases

Article, 41 - 44
Tag this article
Abstract
Full text HTML Full text PDF
The constant ageing of the population has resulted in an increase in chronic conditions such as osteoporosis and neurodegenerative diseases as well as in patient comorbidity. Prolonged immobility, the use of osteopoenia-inducing drugs and an increased risk of falls in patients with neurological diseases have led to an increase in the incidence of fragility fractures, especially of the femur, in these patients. The consequences of these events are often dramatic, being associated with increased mortality, disability and worsening of cognitive and relational functions.
Potent drugs are currently available that can reduce fracture risk by up to 50% with long-term safety and tolerability. Bisphosphonates are the agents most extensively used to prevent fragility fractures. Risedronate has been demonstrated to reduce fracture risk, also in patients with neurological conditions. Considering that osteoporosis requires chronic treatment, patient compliance is extremely important to obtain treatment efficacy.

Vol. XXXIII (No. 4) 2018 October/December

  1. Music and neurorehabilitation: Yes, we can!
    Raglio A.
    doi: 10.11138/FNeur/2018.33.4.173
  2. Clinical and neuroimaging spectrum of hyperglycemia-associated chorea-ballism: systematic review and exploratory analysis of case reports
    Gómez-Ochoa S.A., Espín-Chico B.B., Pinilla-Monsalve G.D., Kaas B.M., Téllez-Mosquera L.E.
    doi: 10.11138/FNeur/2018.33.4.175
  3. Recovery of circadian melatonin rhythm after a melatonin holiday in daytime haemodialysis patients on long-term exogenous melatonin
    Sparla S., Koch B.C., Bosma R., Nagtegaal E.
    doi: 10.11138/FNeur/2018.33.4.188
  4. Multiple sclerosis and non-dystrophic myotonias: do they share a common pathophysiology?
    Portaro S., Naro A., Russo M., Bramanti P., Lauria P., D'Aleo G., La Rosa G., Bramanti A., Calabrò R.S.
    doi: 10.11138/FNeur/2018.33.4.194
  5. From paper to informatics: the Post Soft Care-App, an easy-to-use and fast tool to help therapists identify unmet needs in stroke patients
    De Bartolo D., Morone G., Lupo A., Aloise F., Baricich A., Di Francesco D., Calderone C., Cisari C., Verdecchia G., Sandrini G., Pistarini C., Antonucci G., Smania N., Paolucci S., Iosa M.
    doi: 10.11138/FNeur/2018.33.4.200
  6. Automated mechanical peripheral stimulation and postural control in subjects with Parkinson’s disease and freezing of gait: a randomized controlled trial
    Prusch J.S., Kleiner A.F.R., Salazar A.P., Pinto C., Marchese R.R., Galli M., Pagnussat A.S.
    doi: 10.11138/FNeur/2018.33.4.206
  7. Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations
    Aragona B., De Luca R., Piccolo A., Le Cause M., Destro M., Casella C., Filoni S., Calabrò R.S.
    doi: 10.11138/FNeur/2018.33.4.213
  8. TIA patients with higher ABCD3-I scores are prone to a higher incidence of intracranial stenosis, unstable carotid plaques and multiple-vessel involvement
    Yu Q., Miao W., Han J.
    doi: 10.11138/FNeur/2018.33.4.217
  9. Is there a correlation between urological and cardiovascular dysfunction in Parkinson’s disease?
    Brusa L., Rocchi C., Ponzo V., Stanzione P., Finazzi E., Attanasio A.
    doi: 10.11138/FNeur/2018.33.4.225
  10. Cross-cultural adaptation and validation in the Italian population of the wolf motor function test in patients with stroke
    Berardi A., Dhrami L., Tofani M., Valente D., Sansoni J., Galeoto G.
    doi: 10.11138/FNeur/2018.33.4.229
  11. The dawn of algometry: Paolo Mantegazza’s research on pain
    Cani V.
    doi: 10.11138/FNeur/2018.33.4.254
Last Viewed articles: la lista degli ultimi x visitati.
  1. Anti-osteoporotic treatments in neurological
    diseases

    Giannini S.
credits